RGBP Stock Overview
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Regen BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.70 |
| 52 Week High | US$2.62 |
| 52 Week Low | US$0.40 |
| Beta | 2.79 |
| 1 Month Change | -7.88% |
| 3 Month Change | 2.94% |
| 1 Year Change | -64.10% |
| 3 Year Change | -98.26% |
| 5 Year Change | -66.67% |
| Change since IPO | -99.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| RGBP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.7% | -2.8% | -1.7% |
| 1Y | -64.1% | -0.2% | 22.4% |
Return vs Industry: RGBP underperformed the US Biotechs industry which returned -0.2% over the past year.
Return vs Market: RGBP underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| RGBP volatility | |
|---|---|
| RGBP Average Weekly Movement | 18.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RGBP's share price has been volatile over the past 3 months.
Volatility Over Time: RGBP's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 1 | David Koos | regenbiopharmainc.com |
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is involved in the development of its products, and therapies, including HemaXellarate, a cellular therapeutic product of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6.
Regen BioPharma, Inc. Fundamentals Summary
| RGBP fundamental statistics | |
|---|---|
| Market cap | US$2.92m |
| Earnings (TTM) | -US$774.69k |
| Revenue (TTM) | US$236.56k |
12.3x
P/S Ratio-3.8x
P/E RatioIs RGBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGBP income statement (TTM) | |
|---|---|
| Revenue | US$236.56k |
| Cost of Revenue | US$0 |
| Gross Profit | US$236.56k |
| Other Expenses | US$1.01m |
| Earnings | -US$774.69k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 100.00% |
| Net Profit Margin | -327.48% |
| Debt/Equity Ratio | -13.6% |
How did RGBP perform over the long term?
See historical performance and comparison